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Thirty-five million people are infected by HIV globally, two-
thirds of whom live in sub-Saharan Africa.1 Antiretroviral 
therapy (ART) is a critical intervention for reducing HIV-
related morbidity and mortality, but delivery of ART 
requires multiple laboratory investigations.2 In particular, 
determination of eligibility for ART initiation relies heavily on 
CD4 enumeration, and CD4 results are monitored as the major 
indicator of response to treatment over time. 
The gold standard technique for CD4 enumeration is flow 
cytometry.3,4 Biological and analytical (laboratory) variations 
are known to affect CD4 enumeration; biological factors can 
that influence CD4 results include haemodilution in pregnancy, 
seasonal and diurnal variations (lowest at approximately 12:30 
pm, highest at 8:30 pm), surgery, viral infections, tuberculosis, 
some intercurrent illnesses, corticosteroids, interferon and 
cancer chemotherapy.3 
Laboratory variations are known to occur when enumeration 
techniques different from the gold standard, flow cytometry, are 
used.3,4 In addition, variations are known to be subject to inter-
observer differences as well as inter-laboratory differences.5 
The time to performing CD4 may also cause variation in 
final CD4 count; the World Health Organization (WHO) 
therefore recommends that all CD4 counts be done within 
72 hours from the time of blood collection.3,4 In Swaziland 
and many other parts of southern Africa, blood for CD4 
testing is collected from various health centres and then sent 
to central laboratories where analysis is done. The time of 
arrival of samples differs greatly according to distance from the 
laboratory, but the impact of time differences on CD4 results is 
not well understood. 
Clinicians rely on accurate CD4 values, despite this variability, 
to make decisions regarding ART initiation and management. 
Some previous studies of CD4 variability have produced 
worrying results. Sax and Boswell analysed the implication of 
between-laboratory variations and found that 58% of CD4 count 
results had enough variation to have led to conflicting treatment 
recommendations.6 Pattanapanyasat and Chimma found CD4 
variation between CD4 cell count results conducted using 
flow cytometers of different ages in service.7 Various new CD4 
enumeration techniques, for example the Guava Easy CD4 and 
capillary-based CD4, have been compared with gold-standard 
techniques and found to be comparable.3,4,8 
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Background. Analytical variability in CD4 enumeration 
is well known, but few studies from southern Africa have 
quantified the inter- and intra-laboratory variability in CD4 
count measurements. In addition, the possible impact of 
time lapse after sample collection on CD4 reliability is not 
well understood.
Methods. A cross-sectional study was conducted at 
Royal Swaziland Sugar Corporation Hospital and three 
laboratories, Lab A (comparator), Lab B (national reference) 
and Lab C (rural hospital). Blood from HIV-infected 
individuals was collected using routine venepuncture into 
separate specimens for each of the three laboratories. 
The samples were further subdivided at each laboratory: 
one was run at 12 hours and the second at 24 hours after 
venepuncture. The results of absolute CD4 count and CD4 
percentage testing were compared within (intra-laboratory) 
and between (inter-laboratory) laboratories.
Results. Among 53 participants, the mean CD4 count 
at 12 hours was 373 cells/µl, 396 cells/µl and 439 cells/µl, 
and at 24 hours 359 cells/µl, 389 cells/ µl and 431 cells/µl, 
for laboratories A, B and C, respectively. The coefficient 
of intra-laboratory variation was 4%, 8% and 20% for CD4 
count for laboratories A, B and C, respectively. Comparing 
12- and 24-hour measurements, the mean difference (bias) 
within the laboratories between the two time points (and 
limits of agreement, LOAs) was 14 (-46 to 73), 8 (-161 to 
177) and 7 (20 to 33) cells/µl for labs A, B and C, respectively. 
Comparing Lab A versus Lab B, lab A versus Lab C and Lab 
B versus Lab C, the inter-laboratory bias for the CD4 count 
at 12 hours was -32, -64 and -38 cells/µl, respectively. The 
corresponding LOAs were -213 to 150, -183 to 55, and -300 
to 224, respectively. At 24 hours, the biases and LOAs were 
similar to those at 12 hours.
Conclusions. CD4 counts appeared reliable at all three 
laboratories. Lab B and Lab C were clinically interchangeable 
with the comparator laboratory, Lab A, but not between 
themselves. Time to measurement does not affect the inter-
laboratory agreement within 12 and 24 hours.
S Afr J HIV Med 2012;13(2):59-63.











Ensuring accurate CD4 counts has become 
more important recently, since ART is being 
initiated at higher CD4 counts, when clinical 
signs tend to be less sensitive in detecting 
immune suppression.2 In Swaziland, there 
has been widespread suspicion among HIV 
clinicians regarding discrepancies in CD4 
count results within and between laboratories, 
and concern that these discrepancies may 
potentially be large enough to affect decisions to 
start ART. In order to address this problem, this 
study sought to evaluate the intra- and inter-
laboratory variability in CD4 cell enumeration.
Methods
This study was undertaken at HIV clinics 
at the Royal Swaziland Sugar Corporation 
Hospital in Swaziland and three laboratories, 
Lab A, Lab B and Lab C (identity of the 
laboratories deliberately not disclosed). Lab 
A was a reputable, internationally accredited 
South African laboratory commonly used as 
standard in clinical practice across southern 
Africa. Lab B was the Swazi national 
reference laboratory based in the capital city, 
250 km away from the study setting, and had 
a turnover of 4 000 CD4 enumerations per 





Age (years) (mean (SD)) 37.4 (9.5)







On TB treatment (%) 11.3




Lab A (52 observations) Mean 25th centile 50th centile 75th centile
CD4 count at 12 h (cells/µl) 373 181 336 539
CD4 count at 24 h (cells/µl) 359 177 323 518
CD4 % at 12 h 17 10 15 22
CD4 % at 24 h 17 10 15 21
Lab B (52 observations) Mean 25th centile 50th centile 75th centile
CD4 count at 12 h (cells/µl) 396 185 359 568
CD4 count at 24 h (cells/µl) 389 183 346 535
CD4 % at 12 h 18 11 17 24
CD4 % at 24 h 18 10 17 23
Lab C (51 observations) Mean 25th centile 50th centile 75th centile
CD4 count at 12 h (cells/µl) 439 249 397 611
CD4 count at 24 h (cells/µl) 431 233 396 594
CD4 % at 12 h 18 10 16 22
CD4 % at 24 h 18 10 16 22
Mean time to running CD4 tests (h) First CD4 Second CD4
Lab A 12.0 24.0
Lab B 12.0 24.0
Lab C 12.0 25.1







month. Lab C was a rural mission hospital 
laboratory located 80 km from the study 
site and had a turnover of 1 700 samples per 
month. All the three laboratories used a flow 
cytometric CD4 enumeration method, and 
trained laboratory technicians performed 
the CD4 tests.
To be eligible, patients had to be adults (>18 
years), give informed consent to the study, and 
be visiting the health facility for routine CD4 
count. The study included patients regardless 
of whether they were on ART or not. After 
participants’ consent had been obtained, blood 
was collected into EDTA tubes, using routine 
venepuncture technique, in three aliquots, 
one each for Lab A, Lab C and Lab B. The 
samples were further split into two aliquots 
at each respective laboratory, one of which 
was run at 12 hours and the second at 24 
hours after venepuncture. A reliable transport 
vehicle ensured that specimens reached all 
laboratories within stipulated time.
A sample size of 53 was used. For this type 
of study, Altman and Bland recommend a 
sample size of 30 as ‘minimum acceptable’ 
and 50 as ‘good’ as it gives a 95% confidence 
interval (CI) about ±0.34 s, where s is the 
standard deviation (SD) of the differences 
between measurements by the two methods.9 
Data were analysed using STATA version 10. 
For intra-laboratory variability, the coefficient 
of variation (CV) and Bland-Altman (BA) 
method were used. The BA method was the 
predominant technique for inter-laboratory 
variability. Bland-Altman plots were generated 
in Excel Analyze-it. In both cases, for 
repeatability and agreement, comparison was 
based on clinically significant reference ranges 
used previously in most studies: 0 - 10% for CV, 
Table 2. Intra-laboratory bias and limits of agreement for CD4 count and CD4 percentage at 12 and 24 hours
Limits of agreement Interpretation
Bias (95% CI) Lower (95% CI) Upper (95% CI) Clinically repeatable?
Absolute CD4 count
Lab A 13.5 (5.0 to 21.9) -46.0 (-60.6 to -31.5) 73.0 (58.5 to 87.6) Yes
Lab C 8.2 (-16.0 to 32.4) -160.5 (-202.2 to -118.9) 176.9 (135.3 to 218.6) Yes
Lab B 7.0 (3.2 to 10.7) -19.5 (-25.9 to -13.0) 33.4 (26.9 to 39.9) Yes
CD4 %
Lab A 0.1 (-0.2 to 0.3) -1.7 (-2.2 to -1.3) 1.9 (1.5 to 2.4) Yes
Lab C -0.3 (-0.7 to 0.1) -2.9 (-3.5 to -2.2) 2.3 (1.7 to 3.0) Yes
Lab B 0.1 (-0.3 to 0.5) -2.8 (-3.5 to -2.1) 3.0 (2.3 to 3.7) Yes
*Interpretation based on comparison of limits of agreement with clinically significant range of CV <10%, and ranges for clinical significance: ±19.5% for CD4% ±250 cells/µl for CD4 count.7,8,10,11
Table 3. Inter-laboratory bias and limits of agreement for CD4 count and CD4 percentage at 12 and 24 hours
Laboratories
Limits of agreement Interpretation*
Bias (95% CI) Lower (95% CI) Upper (95% CI) Clinically interchangeable?
CD4 count at 12 h
Lab A/Lab B -31.5 (-57.6 to -5.5) -213.3 (-258.2 to -168.4) 150.2(105.3 to 195.1) Yes
Lab A/Lab C -64.3 (-81.6 to -47.0) -183.8 (-213.6 to -154.0)  55.2 (25.4 to 85.0)  Yes
Lab B/Lab C -38.2 (-75.6 to -0.6)  -300.2 (-364.8 to -235.5) 223.9 (159.2 to 288.5)  No
CD4 %  at 12 h
Lab A/Lab B -1.2 (-2.7 to 0.3) -11.7 (-14.3 to -9.1) 9.3 (6.7 to 11.9) Yes
Lab A/Lab C -0.7 (-1.1 to -0.4)  -3.1 (-3.7 to -2.5)   1.7 (1.1 to 2.2) Yes
Lab B/Lab C 0.5 (-1.1 to 2.1) -10.7 (-13.4 to -7.9) 11.6 (8.9 to 14.4)) Yes
CD4 count at 24 h
Lab A/Lab B -35.6 (-60.0 to -11.1)  -205.7 (-247.6 to -163.7) 134.5 (92.5 to 176.5) Yes
Lab A/Lab C 8.2 (-16.0 to 32.4) -195.0 (-227.6 to -162.5) 65.8 (33.3 to 98.3) Yes
Lab B/Lab C 7.0 (3.2 to 10.7) -265.0 (-321.3 to -208.7) 191.4 (135.0 to 247.7) No
CD4 % at 24 h
Lab A/Lab B -1.2 (-2.5 to 0.2) -10.5 (-12.8 to -8.2) 9.2 (5.7 to 10.5) Yes
Lab A/Lab C -1.1 (-1.6 to -0.5) -4.9 (-5.8 to -3.9)  2.7 (1.8 to 3.6) Yes
Lab B/Lab C 0.1 (-1.3 to 1.5) -9.7 (-12.1 to -7.3) 9.9 (7.4 to 12.3) Yes
*Interpretation based on comparison of limits of agreement with clinically significant range of CV <10%, and ranges for clinical significance: ±19.5% for CD4 % and ±250 cells/µl for CD4 
count.7,8,10,11











±250 cells/µl for CD4 count and 19.5% for CD4 percentage.7,8,10,11 Clinical 
impact on antiretroviral therapy (ART) initiation was assessed by Kappa 
coefficients with comparison to the standard reference scales.12 
Results
Fifty-three participants consented to participate in the study. The mean 
CD4 count was 373 cells/µl, 396 cells/µl and 439 cells/µl at 12 hours, 
and 359 cells/µl, 389 cells/µl and 431 cells/µl at 24 hours, for Lab A, 
Lab B and Lab C, respectively. Subsequent Wilcoxon sign-rank test 
revealed some statistically significant differences in CD4 count between 
the laboratories. Table 1 summarises the demographic, clinical and 
laboratory characteristics of participants.
Intra-laboratory variability. The CV for CD4 count for Lab B 
was low (3.4%) compared with Lab A (8.5%). This was consistent 
with intra-laboratory repeatability based on clinically significant CV 
range of 0 - 10%. For Lab C the CV was 20.1%, a finding consistent 
with poor repeatability. For all three laboratories, the CV of CD4 
percentage was even lower: 5.6%, 8.34% and 7.5% for Lab A, Lab B 
and Lab C, respectively. The results using the BA method showed that 
both CD4 count and CD4 percentage were repeatable, when compared 
with clinically significant ranges ±250 cells/µl and ±19.5%, for all the 
laboratories: for CD4 count, the limits of agreement were -46 cells/ µl 
to 73 cells/µl for Lab A, -20 cells/µl to 33 cells/µl for Lab B, and -161 
cells/µl to 177 cells/µl for Lab C, as per Fig. 1 and Table 2. The BA plots 
for Lab A, Lab B and Lab C had no dispersion suggesting evidence of 
systematic error. 
Inter-laboratory agreement at 12 hours. For CD4 count, at 12 
hours, both Lab C and Lab B could be clinically interchanged with the 
comparator, Lab A, based on the limits of agreement which fell within 
the clinically significant range (defined as ±250 cells/µl): -184 cells/
µl to 55 cells/µl for Lab C, and -213 cells/µl to 150 cells/µl for Lab B, 
which was much wider than for Lab C. When Lab B was compared 
for agreement with Lab C, the limits of agreement were -300 cells/
µl to 224 cells/µl, which were out of the clinically significant range, 
and we therefore concluded that the two laboratories could not be 
clinically interchanged. For CD4 percentage all the laboratories could 
be clinically interchanged. Compared with the comparator, Lab A, 
the limits of agreement for Lab B were -12 cells/µl to 9 cells/µl and 
-3 cells/µl to 2 cells/µl for Lab C; between Lab B and Lab C the limits 
were -11 cells/µl to 12 cells/µl. Table 3 summarises the results for inter-
laboratory variability based on BA results at 12 hours and at 24 hours.
Inter-laboratory agreement at 24 hours. Time to measurement had 
no significant impact on inter-laboratory agreement based on the limits 
of agreement and biases at 24 hours were similar to those at 12 hours for 
both CD4 count and CD4 percentage. When compared with Lab A, the 
limits of agreement at 24 hours were -205 cells/µl to 135 cells/µl for Lab 
B and -195 cells/µl to 66 cells/µl for Lab C. For Lab B/Lab C the limits 
of agreement were -265 cells/µl to 191 cells/µl. For CD4 percentage, all 
the laboratories were clinically interchangeable. The limits of agreement 
were -11% to 9% for Lab A/Lab B, -5% to 3% for Lab A/Lab C and -10% 
to 10% for Lab B/Lab C, which were within the reference range, ±19.5%.
Clinical impact on ART initiation. Compared with Lab A, the 
percentage agreement for ART eligibility was 81% (i.e. 19% of patients 
were misclassified) for Lab B and 89% (11% of patients misclassified) 
for Lab C. For Lab A/Lab B, 23% eligible patients would be misclassified 
and not initiated on ART, as shown in Table 4. 
Discussion
In this study we looked at intra- and inter-laboratory variability, a 
topic that has been investigated previously but for which there are few 
data from southern Africa.5-8,11,13 We also analysed the impact of time 
to measurement on the eventual CD4 result, both within the same 
laboratory and across participating laboratories. CD4 count had good 
repeatability for all the three laboratories, based on preset clinically 
significant ranges. Likewise, CD4 percentage had minimal variation for 
Fig. 1. Bland Altman plots for intra-laboratory variability of CD4 count for 











all the laboratories and even lower CV, a sign 
of stronger repeatability than for CD4 count. 
These findings concurred with previous intra-
laboratory studies.7,8,10,11 
Inter-laboratory variability. Several 
studies on inter-laboratory and inter-
method variability of CD4 count have been 
published and most show good agreement 
and interchangeability.7,10,11 Two studies, 
however, found significant variations across 
different laboratories.5,13 In this study, inter-
laboratory clinical interchangeability results at 
12 and 24 hours showed that agreement was 
independent of time to measurement. The 
limits of agreement were similar when time 
to measurement was 12 hours or 24 hours. 
This finding mirrors the WHO laboratory 
recommendation that CD4 remains stable 
within 72 hours from time of venepuncture.3,4 
Clinicians using the laboratories in this study 
should therefore trust equally CD4 results 
done at 12 hours and 24 hours.
For CD4 percentage, both Lab B and Lab 
C were in agreement with the comparator 
laboratory, Lab A, at 12 and 24 hours with 
narrower limits of agreement than for CD4 
count. Once again, stability of CD4 percentage 
and agreement with the comparator laboratory 
make it a potentially trustworthy and stable 
parameter to use in our setting for possible 
inclusion in guidelines to determine when 
to start ART, as suggested in some previous 
studies.8,10
The degrees of misclassification in this 
study were similar to findings from a study 
by Thakar and Kumar, which found a kappa 
factor range of 74% for a CD4 count below 
350 cells/µl when two laboratories were 
being compared.11 Repeating CD4 count 
measurement and not relying on single CD4 
count results have been known to reduce 
disease misclassification.6 One shortfall of this 
use of misclassification as done here is that it 
does not differentiate between low‐magnitude 
inaccuracy, for example a count of 349 cells/
µl being misclassified as >350 cells/µl, which 
may be reasonably expected from any test, 
and high‐magnitude inaccuracy. A study that 
includes many CD4 values falling close to the 
defined cut‐off (as measured by the reference 
test) will show higher rates of misclassification 
by the new test than a study in which the 
majority of values lie away from the threshold.4
The clinically significant ranges used in 
this study were ±250 cells/µl, ±19.5% and 
CV <10%, because these were the ranges 
used in similar studies which had pre-defined 
ranges.7,8,10,11 The results of repeatability and 
agreement therefore relied on this pre-defined 
range. However, the choice of clinically 
significant ranges is debatable, and a narrower 
range of ±100 cells/µl could have changed 
the interpretation of these results greatly. 
However, the magnitude of CD4 count or CD4 
percentage variability that can affect clinical 
decision making remains poorly defined.13 
The author felt that based on the new ART 
initiation threshold, 350 cells/µl, a range of 
±250 cells is reasonable. 
In conclusion, CD4 count and CD4 
percentage appeared to be repeatable for 
all the three laboratories. Lab B and Lab 
C were clinically interchangeable with the 
comparator laboratory, Lab A, for both CD4 
count and CD4 percentage but not between 
themselves. Time to measurement does not 
affect the inter-laboratory agreement within 
12 and 24 hours. The clinical implications 
of inter-laboratory variation on disease 
misclassification were comparable to those 
from previous studies.
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agreement (%) Kappa Misclassified (%)
Lab A/Lab B 81.1 48.4 0.6 18.9
Lab A/Lab C  88.7 49.9 0.8 11.3
Lab B/Lab C 77.4 50.2   0.6 22.6
*Strength of agreement according to Byrt’s criteria for assessing Kappa strength: excellent agreement  = 0.93 to 1; very good 
agreement = 0.81 to 0.92; good agreement = 0.61 to 0.80; fair agreement = 0.41 to 0.60; slight agreement = 0.21 to 0.40; poor 
agreement = 0.01 to 0.20; no agreement <0.00.12
